Hanall Biopharma (KO:009420) — Stock Price
Hanall Biopharma (KO:009420) is currently trading at ₩56900.00 KRW, up 5.18% today. Over the past 52 weeks, shares have ranged between ₩27100.00 and ₩70700.00. This page tracks Hanall Biopharma's live share price on the KO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Hanall Biopharma (009420) market capitalisation.
Hanall Biopharma (009420) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Hanall Biopharma's daily closing share price and trading volume on the KO exchange over the past year, giving a clear view of recent price momentum and liquidity.
Hanall Biopharma Income Statement — Revenue, Profit & Earnings by Year
Hanall Biopharma's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | ₩138.94 Billion | ₩134.91 Billion | ₩110.00 Billion | ₩101.59 Billion | ₩88.60 Billion |
| Cost of Revenue | ₩65.64 Billion | ₩59.74 Billion | ₩48.02 Billion | ₩41.26 Billion | ₩37.95 Billion |
| Gross Profit | ₩73.31 Billion | ₩75.17 Billion | ₩61.97 Billion | ₩60.33 Billion | ₩50.65 Billion |
| Research & Development | ₩19.99 Billion | ₩23.94 Billion | ₩16.50 Billion | ₩10.46 Billion | ₩9.32 Billion |
| SG&A | ₩29.95 Billion | ₩25.69 Billion | ₩23.24 Billion | ₩20.52 Billion | ₩17.38 Billion |
| Total Operating Expenses | ₩138.71 Billion | ₩132.70 Billion | ₩108.49 Billion | ₩91.50 Billion | ₩82.67 Billion |
| Operating Income | ₩230.47 Million | ₩2.21 Billion | ₩1.51 Billion | ₩10.10 Billion | ₩5.94 Billion |
| EBITDA | — | — | ₩5.00 Billion | ₩11.45 Billion | ₩22.14 Billion |
| EBIT | — | — | ₩1.51 Billion | ₩10.10 Billion | ₩5.94 Billion |
| Interest Expense | ₩70.97 Million | ₩63.86 Million | ₩21.88 Million | ₩25.48 Million | ₩16.01 Million |
| Income Before Tax | ₩-183.20 Million | ₩3.20 Billion | ₩1.93 Billion | ₩8.70 Billion | ₩19.23 Billion |
| Income Tax Expense | — | — | ₩1.68 Billion | ₩-194.05 Million | ₩-539.21 Million |
| Net Income | ₩-1.80 Billion | ₩3.51 Billion | ₩251.47 Million | ₩8.90 Billion | ₩19.76 Billion |
Hanall Biopharma Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Hanall Biopharma's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | ₩212.88 Billion | ₩239.75 Billion | ₩213.45 Billion | ₩198.48 Billion | ₩220.13 Billion |
| Total Current Assets | ₩85.35 Billion | ₩113.58 Billion | ₩111.79 Billion | ₩118.81 Billion | ₩129.36 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | ₩8.32 Billion | ₩22.77 Billion | ₩37.09 Billion | ₩67.78 Billion | ₩86.51 Billion |
| Net Receivables | ₩15.33 Billion | ₩15.63 Billion | ₩26.69 Billion | ₩9.86 Billion | ₩11.55 Billion |
| Inventory | ₩37.70 Billion | ₩32.38 Billion | ₩25.18 Billion | ₩20.41 Billion | ₩19.89 Billion |
| Property, Plant & Equipment | — | — | ₩19.13 Billion | ₩19.04 Billion | ₩15.48 Billion |
| Goodwill | — | — | — | — | — |
| Total Liabilities | ₩44.53 Billion | ₩53.53 Billion | ₩45.19 Billion | ₩34.99 Billion | ₩38.86 Billion |
| Total Current Liabilities | ₩34.72 Billion | ₩37.65 Billion | ₩28.53 Billion | ₩22.12 Billion | ₩23.07 Billion |
| Long-term Debt | — | — | — | — | — |
| Net Debt | — | — | — | — | — |
| Total Stockholder Equity | ₩168.35 Billion | ₩186.22 Billion | ₩168.26 Billion | ₩163.49 Billion | ₩181.27 Billion |
| Retained Earnings | ₩26.49 Billion | ₩31.36 Billion | ₩29.41 Billion | ₩26.38 Billion | ₩17.59 Billion |
Hanall Biopharma Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Hanall Biopharma generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₩9.36 Billion | ₩29.64 Billion | ₩25.20 Billion | ₩839.87 Million | ₩929.29 Million |
| Capital Expenditures | ₩23.07 Billion | ₩9.20 Billion | ₩2.83 Billion | ₩4.61 Billion | ₩2.56 Billion |
| Free Cash Flow | ₩-13.71 Billion | ₩20.45 Billion | ₩17.53 Billion | ₩-8.16 Billion | ₩-6.46 Billion |
| Investing Cash Flow | — | — | ₩-10.59 Billion | ₩8.03 Billion | ₩-2.32 Billion |
| Financing Cash Flow | — | — | ₩-10.64 Billion | ₩-306.53 Million | ₩-519.35 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | ₩584.26 Million | ₩1.62 Billion | ₩1.87 Billion | ₩1.62 Billion | ₩794.30 Million |
| Depreciation | ₩3.12 Billion | ₩3.25 Billion | ₩3.05 Billion | ₩2.72 Billion | ₩2.89 Billion |
| Change in Cash | ₩-17.34 Billion | ₩16.88 Billion | ₩4.05 Billion | ₩8.59 Billion | ₩-1.92 Billion |
Hanall Biopharma Earnings History — EPS Actual vs. Analyst Estimates
Track Hanall Biopharma's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Apr 28, 2026 | — | — | — |
| Jan 20, 2026 | — | — | — |
| Oct 28, 2025 | 5.83 | — | — |
| Jul 23, 2025 | 11.79 | — | — |
| Apr 30, 2025 | -4.00 | 6.89 | -158.06% |
| Jan 22, 2025 | 31.91 | — | — |
| Oct 29, 2024 | 4.00 | 19.34 | -79.32% |
| Jul 25, 2024 | -66.00 | 14.57 | -552.99% |